Last reviewed · How we verify
Transdermal Neostigmine and Glycopyrrolate
Transdermal Neostigmine and Glycopyrrolate is a Small molecule drug developed by James J. Peters Veterans Affairs Medical Center. It is currently in Phase 1 development.
At a glance
| Generic name | Transdermal Neostigmine and Glycopyrrolate |
|---|---|
| Sponsor | James J. Peters Veterans Affairs Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics of Neostigmine and Glycopyrrolate (EARLY_PHASE1)
- Transdermal Administration by a Novel Wireless Iontophoresis Device (EARLY_PHASE1)
- Neostigmine and Glycopyrrolate by Iontophoresis (PHASE3)
- Use of a Prokinetic Agent as an Adjunct to Thrice Weekly Bowel Care After SCI (PHASE1)
- Use of High Resolution Colonic Manometry in Studying Motility (PHASE1)
- Use of Prokinetics During Inpatient Bowel Care for SCI Patients (PHASE1)
- Transdermal Administration of a Prokinetic Agent for Bowel Evacuation in Persons With SCI (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transdermal Neostigmine and Glycopyrrolate CI brief — competitive landscape report
- Transdermal Neostigmine and Glycopyrrolate updates RSS · CI watch RSS
- James J. Peters Veterans Affairs Medical Center portfolio CI
Frequently asked questions about Transdermal Neostigmine and Glycopyrrolate
What is Transdermal Neostigmine and Glycopyrrolate?
Transdermal Neostigmine and Glycopyrrolate is a Small molecule drug developed by James J. Peters Veterans Affairs Medical Center.
Who makes Transdermal Neostigmine and Glycopyrrolate?
Transdermal Neostigmine and Glycopyrrolate is developed by James J. Peters Veterans Affairs Medical Center (see full James J. Peters Veterans Affairs Medical Center pipeline at /company/james-j-peters-veterans-affairs-medical-center).
What development phase is Transdermal Neostigmine and Glycopyrrolate in?
Transdermal Neostigmine and Glycopyrrolate is in Phase 1.